



Dedicated To Life

April 18, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: News clarification on "SEC approves two-dose regimen of Zydus Covid-19 vaccine ZyCoV-D"

Ref.: Email dated April 18, 2022 received from both the stock exchanges

Dear Sir / Madam,

With reference to the email dated April 18, 2022, seeking clarification on the captioned news item, we hereby clarify that the Company has not received any official communication for the permission of 2-dose regimen of ZyCoV-D.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

(Formerly known as CADILA HEALTHCARE LIMITED)

DHAVAL N. SONI

COMPANY SECRETARY

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

